It took just one off-hand comment during a White House event about fertility treatments for President Trump to temporarily wipe tens of billions from the market cap of the world’s leading obesity drugmakers. Trump’s vow Thursday to bring Ozempic down to $150 per month, calling it “the fat-loss drug,” sent Novo Nordisk shares down 6.3%… The post Trump’s $150 Ozempic vow hits Novo, Lilly, even as Oz says ‘we have not negotiated those yet’ appeared first on Drug Discovery and Dev...
